The National Immunisation Advisory Committee has recommended that AstraZeneca Covid-19 vaccinations can resume in Ireland.
The vaccine was temporarily deferred last Sunday following reports of blood clots in recipients in Norway.
The European Medicines Agency concluded yesterday that the vaccine is not associated with an increase in the overall risk of blood clots in those who receive it. The EMA said the benefits of the COVID-19 Vaccine AstraZeneca in combating the threat of COVID-19 continue to outweigh the risk of side effects.
Deputy Chief Medical Officer Dr Ronan Glynn has today recommended that AstraZeneca vaccinations can now resume.
Over 117,000 doses of COVID-19 Vaccine AstraZeneca have been administered in Ireland.
To date, no reports of serious clotting events associated with low platelets have been received by the Health Products Regulatory Authority (HPRA) in Ireland.
The HSE will work to recommence the administration of COVID-19 Vaccine AstraZeneca.